Targeted Therapeutics: Linking EGF Receptor Drugs to Diagnostics
Executive Summary
Herceptin-HerceptTest is a successful model of the benefits of linking a therapeutic to a diagnostic test, but the ties aren't as clear-cut in the next crop of targeted therapies to come to market. EGF receptor-based drugs work on specific receptor targets in a variety of cancers, but scientists haven't been able so far to correlate patient response to the drugs to receptor presence or quantity. Yet the issue is extremely important, both to pharma companies seeking to determine how they will design their clinical trials and submit data to the FDA and to diagnostic companies looking for a new kind of market.
You may also be interested in...
Problems With Biomarkers: A Tale of Three Drugs
Enthusiasm for biomarkers to guide drug development and clinical decision making is high, but given how little we know about them, biomarkers are a risky investment, as shown by experiences with EGFR inhibitors.
Problems With Biomarkers: A Tale of Three Drugs
Enthusiasm for biomarkers to guide drug development and clinical decision making is high, but given how little we know about them, biomarkers are a risky investment, as shown by experiences with EGFR inhibitors.
The Outlook for Pharmacogenomics Testing in Primary Care
The FDA sees pharmacogenomics as a key tool for optimizing both the development and clinical utility of drugs. But most of the visible examples to date of pharmacogenomics have been in specialty areas like oncology and virology. The Vioxx situation raises an inevitable question as Pharma looks to improve R&D efficiency and clinical utility. What is the role of pharmacogenomics in assessing the safety and efficacy of primary care drugs?